Frazier Financial Advisors’s PTC Therapeutics PTCT Stock Holding History

Frazier Financial Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5	Closed	-$341	–	794
2026 Q1	$341	Buy	+5	New	+$354	﹤0.01%	769

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Frazier Financial Advisors's PTCT Position: Q2 2026 in Review

Frazier Financial Advisors sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 5 shares — an estimated $341 sold.

Frazier Financial Advisors first reported a position in PTCT in Q1 2026 and held it in 1 quarter. The position peaked at $341 in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Frazier Financial Advisors reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
Frazier Financial Advisors sold 5 PTC Therapeutics shares in Q2 2026, an estimated $341.
Frazier Financial Advisors first reported a position in PTC Therapeutics in Q1 2026 and held it in 1 quarter.
Frazier Financial Advisors's PTC Therapeutics position peaked at $341 in Q1 2026.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Frazier Financial Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.